125683 Apr 2026

As of April 2026, here is an informative review of the clinical and regulatory findings associated with this product, specifically focusing on the data submitted under regarding infusion rate increases. Clinical Review of Xembify (STN: 125683)

High concentration (20%) allows for lower infusion volumes and faster delivery. Generally well-tolerated at rates up to 35 mL/hour/site. Primary Risks 125683

: While the Statistical Review noted some limitations due to small sample sizes in higher-rate groups, they concluded there were no major statistical issues that would prevent the labeling changes. As of April 2026, here is an informative

The reference corresponds to the Biologics License Application (BLA) for Xembify (Immune Globulin Subcutaneous [Human], 20%), a subcutaneous immunoglobulin (SCIG) therapy manufactured by Grifols . Primary Risks : While the Statistical Review noted

: This increase allows for significantly shorter infusion times, which is a major factor in treatment adherence and quality of life for patients requiring long-term immune globulin replacement therapy.